Elekta established its reputation with the Leksell Gamma Knife for neurosurgery. Now, after a turnaround, it is expanding into a comprehensive cancer care company.
By Stephen Levin
Assume you are the president and CEO of a publicly-traded, technology-driven medical device company. For the first 15 years of...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
